Search
Benoxaprofen
go.drugbank.com/drugs/DB04812ApprovedWithdrawnThe use of benoxaprofen, formerly marketed as Oraflex tablets, was associated with fatal cholestatic jaundice among other serious adverse reactions.
Kappadione
go.drugbank.com/drugs/DB09332ApprovedKappadione is a Vitamin K derivative (chemically, it is menadiol sodium diphosphate), previously approved by FDA prior to 1982 and marketed by Lilly Marketing for this drug has been discontinued and is
Tizanidine
go.drugbank.com/drugs/DB00697ApprovedInvestigationalInitially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons … It may also be caused by musculoskeletal injury [A177583]. Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition.
Drotaverine
go.drugbank.com/drugs/DB06751ApprovedWithdrawn[A231619] Drotaverine is not approved by the FDA, European Medicines Agency, or Health Canada. It is approved for use in Thailand as oral tablets or intramuscular injections.[L22689] … Drotaverine is an antispasmodic drug that works by inhibiting phosphodiesterase-4 (PDE4).
Fosdenopterin
go.drugbank.com/drugs/DB16628Approved[L43075] In September 2022, the EMA approved the use of fosdenopterin.[L43372,L43433] … In July 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended fosdenopterin be granted marketing authorization under exceptional circumstances for the treatment of patients
Ziconotide
go.drugbank.com/drugs/DB06283ApprovedInvestigational[L13389] To date, ziconotide is the only calcium channel blocking peptide approved for use by the FDA.[A202835] … [A202829, A202835, A202838, A202841, A202850, A202859, L13389] Ziconotide was granted FDA approval on December 28, 2004 for marketing by TerSera therapeutics LLC. under the name Prialt.
Guanethidine
go.drugbank.com/drugs/DB01170ApprovedWithdrawnAn antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. … It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.
Tenofovir alafenamide
go.drugbank.com/drugs/DB09299ApprovedInvestigational[T239] Tenofovir alafenamide is an alanine ester form characterized for presenting low systemic levels but high intracellular concentration. … [L4388,L9010] Tenofovir alafenamide was developed by Gilead Sciences Inc and granted FDA approval on 5 November 2015.[L6271]
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseQuercus rubra pollen
go.drugbank.com/drugs/DB10481ApprovedQuercus rubra pollen is the pollen of the Quercus rubra plant. Quercus rubra pollen is mainly used in allergenic testing.
Mixtures: 5-oak Mix, Blackjack/bur/post/red/white Pollen